Skip to main content

Table 5 Economic results of the models evaluating routine varicella vaccination (2010 EUR, German price level)

From: Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries

Study Age at vaccination Dose schedule Comparator Health care payer perspective Societal perspective
Banz et al. [35] 15 months 1 No vaccination BCR 1.75 BCR 4.12
11-12 yearsa 1 No vaccination BCR 1.13 BCR 8.44
combined 1 No vaccination BCR 1.70 BCR 4.10
Banz et al. [51] 1-2 years 2 2-dose vaccination at 11–15 yearsa BCR 0.30; EUR 856/LYG BCR 1.29
Beutels et al. [37] 15 months 1 No vaccination BCR 0.82; EUR 14,700/LYG BCR 4.60
12 yearsa 1 No vaccination BCR 1.94 BCR 6.02
Bilcke et al. [30] 1 year (95 % coverage) 1 No vaccination EUR 550–14,140/QALY NA
1 year (1st dose, 95 % coverage); 4 years (2nd dose, 90 % coverage) 2 No vaccination EUR 5,240-31,942/QALY NA
1 year (1st dose, 95 % coverage); 11 years (2nd dose, 80 % coverage) 2 No vaccination EUR 5,043-29,775/QALY NA
1 year (1st dose, 50 % coverage); 4 years (2nd dose, 50 % coverage) 2 No vaccination EUR 3,345-23,240/QALY NA
All vaccination options (including and excluding additional HZ vaccination) 2 No vaccination Net QALY loss for many time horizonsb; EUR 36,256-135,961/LYGb NA
Bonanni et al. [36] 12-18 months 2 No vaccination BCR 0.67 BCR 3.47
13 years 2 No vaccination BCR 0.36 BCR 2.60
Brisson et al. [31] 12 months 1 No vaccination BCR 0.61; EUR 38,142/LYG BCR 5.24
12 months 1 No vaccination BCR 0.59c; EUR 40,193/LYGc BCR 5.09c
12 months 1 No vaccination BCR 0.16b; EUR 101,296/LYGb NA
12 yearsa 1 No vaccination BCR 0.73; EUR 15,863/LYG BCR 4.44
Brisson et al. [32] Infants 1 No vaccination Net QALY lossb Net QALY lossb
11 yearsa 1 No vaccination EUR 26,110/QALYb Cost-savingb
Coudeville et al. [52] <6 years 1 No vaccination Net benefit EUR 326.8 million NA
Coudeville et al. [53] 12-36 months 1 No vaccination BCR 1.20 at high vaccination coverage BCR 3.50 at high vaccination coverage
Coudeville et al. [54] 12-36 months 1 No vaccination Cost-saving at high vaccination coverage (Germany 51 %; France 6.7 %); EUR 6.960/LYG at low vaccination coverage (France; cost-saving in Germany) Cost-saving at high vaccination coverage (Germany 61 %; France 60 %)
DIez Domingo et al. [55] 15 months 1 No vaccination BCR 0.54 BCR 1.61
Getsios et al. [56] 12 months 1 No vaccination EUR 71,722/QALY; EUR 36/varicella case avoided Cost-saving
Ginsberg & Somekh [57] 12 months 1 No vaccination BCR 1.63 BCR 19.33
Hammerschmidt et al. [58] 11-23 months (including a catch-up of 2–17 year oldsa) 2 (1 dose for catch-up) 1-dose vaccination at 12–15 yearsa BCR 1.08 BCR 2.56
Huse et al. [59] 15 months 1 No vaccination NA Cost-saving (net benefit of EUR 86.28 per vaccinee)
Lenne et al. [60] 1-2 years 1 No vaccination BCR 0.91; EUR 5,202/LYG BCR 3.70
Lieu et al. [61] <6 years 1 No vaccination BCR 0,90; EUR 21,648/LYG; EUR 5.68/varicella case prevented BCR 5.40
Preblud et al. [62] 15 months 1 No vaccination BCR 0.30 BCR 6.90 (including home care costs)
Scuffham et al. [63] 15 months 1 No routine vaccination but low private coverage BCR 0.67 BCR 2.79
Scuffham et al. [34] 12 months 1 No vaccination EUR 49.11/varicella case avoided; EUR 16,439/hospitalisation avoided NA
12 yearsa 1 No vaccination EUR 404.81/varicella case avoided; EUR 26,791/hospitalisation avoided NA
Thiry et al. [64] 11 yearsa 1 No vaccination BCR 0.54; EUR 26,988/LYG BCR 2.17
van Hoek et al. [33] 1 year (first dose); 3 years (second dose) 2 No vaccination 41 % of the simulations below GBP 20,000/QALY (EUR 26,576/QALY)b; 50 % of the simulations below GBP 30,000/QALY (EUR 39,864/QALY)b NA
1 year (first dose); 3 years (second dose) + HZ vaccination of the elderly 2 No vaccination 50 % of the simulations below GBP 20,000/QALY (EUR 26,576/QALY)b; 70 % of the simulations below GBP 30,000/QALY (EUR 39,864/QALY)b NA
Zhou et al. [29] Children 1 No vaccination BCR 1.00 BCR 4.37
Children 2 No vaccination BCR 0.61 BCR 2.73
Children 2 1-dose vaccination BCR 0.13 BCR 0.56; EUR 95,584/QALY
  1. BCR benefit-cost ratio; LYG life-year gained; QALY quality-adjusted life-year; NA not applicable
  2. aWith a negative or uncertain history of varicella
  3. bIncluding the impact on HZ
  4. cIncluding the impact of breakthrough varicella